Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Common Equity (2020 - 2025)

Historic Common Equity for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $141.8 million.

  • Caribou Biosciences' Common Equity fell 4955.78% to $141.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.8 million, marking a year-over-year decrease of 4955.78%. This contributed to the annual value of $253.0 million for FY2024, which is 3133.81% down from last year.
  • Caribou Biosciences' Common Equity amounted to $141.8 million in Q3 2025, which was down 4955.78% from $166.1 million recorded in Q2 2025.
  • Caribou Biosciences' 5-year Common Equity high stood at $404.4 million for Q3 2021, and its period low was -$47.7 million during Q2 2021.
  • In the last 5 years, Caribou Biosciences' Common Equity had a median value of $300.9 million in 2022 and averaged $267.4 million.
  • Within the past 5 years, the most significant YoY rise in Caribou Biosciences' Common Equity was 370718.04% (2021), while the steepest drop was 120125.51% (2021).
  • Quarter analysis of 5 years shows Caribou Biosciences' Common Equity stood at $387.8 million in 2021, then decreased by 22.42% to $300.9 million in 2022, then grew by 22.44% to $368.4 million in 2023, then tumbled by 31.34% to $253.0 million in 2024, then tumbled by 43.92% to $141.8 million in 2025.
  • Its Common Equity stands at $141.8 million for Q3 2025, versus $166.1 million for Q2 2025 and $217.2 million for Q1 2025.